Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.California-based Cortex Pharmaceuticals, a neuro-science company focused on novel drug therapies for treating psychiatric disorders, neurological diseases and sleep apnea, has announced top-line results from an exploratory clinical study with its AMPAKINE compound CX1739 in subjects with sleep apnea.
Subscribe to our email newsletter
The objective of the study was to explore safety and tolerability in the sleep apnea population, and assess putative efficacy of CX1739 on a range of sleep apnea parameters assessed by overnight polysomnography.
According to the study selected oxygen saturation parameters were statistically improved by one dose of CX1739.
While CX1739 did not reduce the mean apnea/hypopnea index, it significantly reduced the apnea/hypopnea time.
A number of blood oxygenation measurements also showed statistically discernible improvements.
Cortex president and CEO Mark Varney said repeated daily treatment with CX1739 for several weeks may improve sleep apnea symptoms in subjects who did not respond after a single dose.
"Testing this drug in a population which suffers from predominantly central apneas holds potential for Cortex," Varney said.